Literature DB >> 2839629

Antihypertensive activity of enalapril. Effect of ibuprofen and different salt intakes.

P Minuz1, A Lechi, E Arosio, M Degan, M G Capuzzo, C Lechi, M Corsato, A Dalla Riva, G P Velo.   

Abstract

It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may also act through the renal prostaglandin (PG) system; moreover, it has been shown that nonsteroidal antiinflammatory drugs (NSAIDs) are capable of reducing the antihypertensive activity of ACE inhibitors. Sixteen essential hypertensive patients (WHO stages, I-II, eight on a low-sodium diet and eight on a high-sodium diet) were treated with enalapril, 20 mg/day per os, for 4 days. On days 3 and 4, ibuprofen, 1,200 mg/day per os, was also given. Enalapril reduced blood pressure, particularly in the group on the low-sodium diet. Urinary 6-keto-PGF1 alpha, an indicator of renal PGI2 production (determined by HPLC-RIA), increased in the first few hours after enalapril in the low-sodium group. Ibuprofen did not reduce the antihypertensive effect of enalapril, nor did it affect plasma renin activity or plasma aldosterone. Only a slight reduction in 6-keto-PGF1 alpha excretion was observed after enalapril plus ibuprofen. It is suggested that the effect of enalapril on urinary 6-keto-PGF1 alpha excretion is largely dependent on factors such as sodium intake.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2839629

Source DB:  PubMed          Journal:  J Clin Hypertens        ISSN: 0748-450X            Impact factor:   3.738


  4 in total

1.  Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Authors:  Mai Duong; Francesco Salvo; Antoine Pariente; Abdelilah Abouelfath; Regis Lassalle; Cecile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

3.  The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension.

Authors:  W G Rapeport; V C Grimwood; J Hosie; P M Sloan; K Korlipara; B D Silvert; I James; G L Mechie; J L Anderton
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.